Cite
HARVARD Citation
Sadiq, M. et al. (2022). Characterisation of pharmacokinetics, safety and tolerability in a first‐in‐human study for AZD8154, a novel inhaled selective PI3Kγδ dual inhibitor targeting airway inflammatory disease. British journal of clinical pharmacology. 88 (1), pp. 260-270. [Online].